These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 23792499)

  • 1. Safety and effects of prophylactic defibrotide for sinusoidal obstruction syndrome in hematopoietic stem cell transplantation.
    Park M; Park HJ; Eom HS; Kwon YJ; Park JA; Lim YJ; Yoon JH; Kong SY; Ghim TT; Lee HW; Yun T; Park BK
    Ann Transplant; 2013 Jan; 18():36-42. PubMed ID: 23792499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial.
    Corbacioglu S; Cesaro S; Faraci M; Valteau-Couanet D; Gruhn B; Rovelli A; Boelens JJ; Hewitt A; Schrum J; Schulz AS; Müller I; Stein J; Wynn R; Greil J; Sykora KW; Matthes-Martin S; Führer M; O'Meara A; Toporski J; Sedlacek P; Schlegel PG; Ehlert K; Fasth A; Winiarski J; Arvidson J; Mauz-Körholz C; Ozsahin H; Schrauder A; Bader P; Massaro J; D'Agostino R; Hoyle M; Iacobelli M; Debatin KM; Peters C; Dini G
    Lancet; 2012 Apr; 379(9823):1301-9. PubMed ID: 22364685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defibrotide for Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study.
    Richardson PG; Smith AR; Triplett BM; Kernan NA; Grupp SA; Antin JH; Lehmann L; Shore T; Iacobelli M; Miloslavsky M; Hume R; Hannah AL; Nejadnik B; Soiffer RJ;
    Biol Blood Marrow Transplant; 2017 Jun; 23(6):997-1004. PubMed ID: 28285079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defibrotide for children and adults with hepatic veno-occlusive disease post hematopoietic cell transplantation.
    Corbacioglu S; Richardson PG
    Expert Rev Gastroenterol Hepatol; 2017 Oct; 11(10):885-898. PubMed ID: 28825848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Defibrotide in the prevention and treatment of veno-occlusive disease in autologous and allogeneic stem cell transplantation in children.
    Qureshi A; Marshall L; Lancaster D
    Pediatr Blood Cancer; 2008 Apr; 50(4):831-2. PubMed ID: 18286502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation.
    Dignan FL; Wynn RF; Hadzic N; Karani J; Quaglia A; Pagliuca A; Veys P; Potter MN; ;
    Br J Haematol; 2013 Nov; 163(4):444-57. PubMed ID: 24102514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Earlier defibrotide initiation post-diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation.
    Richardson PG; Smith AR; Triplett BM; Kernan NA; Grupp SA; Antin JH; Lehmann L; Miloslavsky M; Hume R; Hannah AL; Nejadnik B; Soiffer RJ
    Br J Haematol; 2017 Jul; 178(1):112-118. PubMed ID: 28444784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defibrotide treatment but not prophylaxis is useful in hepatic sinusoidal obstruction syndrome in children undergoing autologous stem cell transplant following high-dose chemotherapy: A single-center experience from the Royal Marsden Hospital, UK.
    Roy Moulik N; Johnson I; Van Bruggen L; Petterson T; Mycroft J; Vaidya SJ
    Pediatr Blood Cancer; 2020 Nov; 67(11):e28677. PubMed ID: 32865880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defibrotide for Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease Prophylaxis in High-Risk Adult Patients: A Single-Center Experience Study.
    Picod A; Bonnin A; Battipaglia G; Giannotti F; Ruggeri A; Brissot E; Malard F; Médiavilla C; Belhocine R; Vekhoff A; Gueye MS; Lapusan S; Adaeva R; Isnard F; Legrand O; Baylatry MT; Joly AC; Labopin M; Duléry R; Mohty M
    Biol Blood Marrow Transplant; 2018 Jul; 24(7):1471-1475. PubMed ID: 29477779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defibrotide sodium for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome.
    Richardson PG; Triplett BM; Ho VT; Chao N; Dignan FL; Maglio M; Mohty M
    Expert Rev Clin Pharmacol; 2018 Feb; 11(2):113-124. PubMed ID: 29301447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of sinusoidal obstruction syndrome with defibrotide: a single-center experience.
    Sucak GT; Aki ZS; Yagcí M; Yegin ZA; Ozkurt ZN; Haznedar R
    Transplant Proc; 2007 Jun; 39(5):1558-63. PubMed ID: 17580188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome following nontransplant-associated chemotherapy: Final results from a post hoc analysis of data from an expanded-access program.
    Kernan NA; Richardson PG; Smith AR; Triplett BM; Antin JH; Lehmann L; Messinger Y; Liang W; Hume R; Tappe W; Soiffer RJ; Grupp SA
    Pediatr Blood Cancer; 2018 Oct; 65(10):e27269. PubMed ID: 29873895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of defibrotide in blood and marrow transplantation.
    Richardson PG; Carreras E; Iacobelli M; Nejadnik B
    Blood Adv; 2018 Jun; 2(12):1495-1509. PubMed ID: 29945939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defibrotide for the management of sinusoidal obstruction syndrome in patients who undergo haemopoietic stem cell transplantation.
    Coutsouvelis J; Avery S; Dooley M; Kirkpatrick C; Spencer A
    Cancer Treat Rev; 2016 Nov; 50():200-204. PubMed ID: 27721142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Prophylaxis of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome With Defibrotide After Hematopoietic Stem Cell Transplantation in Children: Single Center Experience.
    Karagun BS; Akbas T; Erbey F; Sasmaz İ; Antmen B
    J Pediatr Hematol Oncol; 2022 Jan; 44(1):e35-e39. PubMed ID: 34966102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful treatment with defibrotide for sinusoidal obstruction syndrome after hematopoietic stem cell transplantation.
    Yakushijin K; Matsui T; Okamura A; Yamamoto K; Ito M; Chihara K
    Kobe J Med Sci; 2005; 51(3-4):55-65. PubMed ID: 16444097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defibrotide plus best standard of care compared with best standard of care alone for the prevention of sinusoidal obstruction syndrome (HARMONY): a randomised, multicentre, phase 3 trial.
    Grupp SA; Corbacioglu S; Kang HJ; Teshima T; Khaw SL; Locatelli F; Maertens J; Stelljes M; Stepensky P; Lopez P; Amber V; Pagliuca A; Richardson PG; Mohty M
    Lancet Haematol; 2023 May; 10(5):e333-e345. PubMed ID: 37001534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pooled analysis of Day 100 survival for defibrotide-treated patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome and ventilator or dialysis dependence following haematopoietic cell transplantation.
    Richardson PG; Smith AR; Kernan NA; Lehmann L; Soiffer RJ; Ryan RJ; Tappe W; Grupp S
    Br J Haematol; 2020 Aug; 190(4):583-587. PubMed ID: 32157682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Defibrotide therapy for patients with sinusoidal obstruction syndrome after hematopoietic stem cell transplantation].
    Yakushijin K; Okamura A; Ono K; Kawano Y; Kawano H; Funakoshi Y; Kawamori Y; Nishikawa S; Minagawa K; Sada A; Shimoyama M; Yamamoto K; Katayama Y; Matsui T
    Rinsho Ketsueki; 2009 Jan; 50(1):3-8. PubMed ID: 19225222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylactic recombinant thrombomodulin treatment prevents hepatic sinusoidal obstruction syndrome in high-risk pediatric patients that undergo hematopoietic stem cell transplants.
    Yamamoto S; Toyama D; Sugishita Y; Kaneko R; Okamoto N; Koganesawa M; Fujita S; Akiyama K; Matsuno R; Isoyama K
    Pediatr Transplant; 2018 Nov; 22(7):e13269. PubMed ID: 30003636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.